The Rockefeller University has licensed its portfolio of broadly neutralizing antibodies (bNAbs) against HIV—including the two clinical-stage agents 3BNC117 and 10-1074 to Gilead Sciences (GILD). These investigational agents have the potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies.
Rockefeller University Intellectual Property
The research center has been busy the past few years developing HIV bNAbs, a class of immunotherapy agents that were initially derived from HIV infected individuals with a strong anti-HIV immunologic response and were thus designed to target HIV, mainly originating from the latent viral reservoir. The research center’s initial preclinical and clinical research reveals that HIV bNAbs can produce an enhanced, prolonged immune response to HIV, representing a promising new approach for HIV treatment or prevention in combination with other long-acting agents, or prolonged virologic remission in the absence of antiretroviral use.
This licensing agreement offers an additional pathway for innovations in Gilead’s HIV pipeline in areas of evolving and unmet medical needs.
In this deal, Gil...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).